$3.06 Billion is the total value of BRAIDWELL LP's 82 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NANOSTRING TECHNOLOGIES INCnote 2.625% 3/0 | $115,400,772 | -5.3% | 145,520,000 | 0.0% | 3.77% | -6.1% | ||
| NEVRO CORPnote 2.750% 4/0 | $100,947,924 | -1.7% | 109,251,000 | 0.0% | 3.30% | -2.6% | ||
| TRAVERE THERAPEUTICS INCnote 2.500% 9/1 | $50,500,740 | -6.3% | 56,031,000 | 0.0% | 1.65% | -7.2% | ||
| IONIS PHARMACEUTICALS INCnote 4/0 | $50,004,113 | +3.9% | 52,740,000 | 0.0% | 1.63% | +3.0% | ||
| KARYOPHARM THERAPEUTICS INCnote 3.000%10/1 | $43,016,352 | -15.9% | 65,976,000 | 0.0% | 1.41% | -16.7% | ||
| INSMED INCnote 1.750% 1/1 | $38,004,813 | +4.2% | 39,963,000 | 0.0% | 1.24% | +3.2% | ||
| NEOGENOMICS INCnote 0.250% 1/1 | $36,082,568 | +0.2% | 48,678,000 | 0.0% | 1.18% | -0.8% | ||
| HROW | HARROW HEALTH INC | $27,656,324 | -10.0% | 1,452,538 | 0.0% | 0.90% | -10.8% | |
| AMYRIS INCnote 1.500%11/1 | $26,191,500 | -33.0% | 137,850,000 | 0.0% | 0.86% | -33.6% | ||
| DBVT | DBV TECHNOLOGIES S Asponsored adr | $23,004,792 | +12.4% | 12,107,785 | 0.0% | 0.75% | +11.4% | |
| TRAVERE THERAPEUTICS INCnote 2.250% 3/0 | $22,804,031 | -18.2% | 28,350,000 | 0.0% | 0.74% | -18.9% | ||
| ENTA | ENANTA PHARMACEUTICALS INC | $22,219,834 | -47.1% | 1,038,310 | 0.0% | 0.73% | -47.6% | |
| DYN | DYNE THERAPEUTICS INC | $15,501,060 | -2.3% | 1,377,872 | 0.0% | 0.51% | -3.4% | |
| INVITAE CORPnote 2.000% 9/0 | $14,968,713 | +0.9% | 16,781,000 | 0.0% | 0.49% | -0.2% | ||
| MINERALYS THERAPEUTICS INC | $9,382,615 | +8.9% | 550,300 | 0.0% | 0.31% | +8.1% | ||
| ALXO | ALX ONCOLOGY HLDGS INC | $9,386,749 | +66.2% | 1,249,900 | 0.0% | 0.31% | +65.1% | |
| NUVB | NUVATION BIO INC | $7,421,220 | +8.4% | 4,122,900 | 0.0% | 0.24% | +7.1% | |
| ADPT | ADAPTIVE BIOTECHNOLOGIES COR | $4,351,106 | -24.0% | 648,451 | 0.0% | 0.14% | -24.9% | |
| INSMED INCnote 0.750% 6/0 | $2,953,125 | +8.5% | 3,500,000 | 0.0% | 0.10% | +6.7% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| GUARDANT HEALTH INC | 4 | Q3 2023 | 6.3% |
| EXACT SCIENCES CORP | 4 | Q3 2023 | 4.4% |
| NOVOCURE LTD | 4 | Q3 2023 | 3.9% |
| NANOSTRING TECHNOLOGIES INC | 4 | Q3 2023 | 4.0% |
| NEVRO CORP | 4 | Q3 2023 | 3.4% |
| BRIDGEBIO PHARMA INC | 4 | Q3 2023 | 3.5% |
| ALPHATEC HLDGS INC | 4 | Q3 2023 | 3.6% |
| GLAUKOS CORP | 4 | Q3 2023 | 3.0% |
| VAXCYTE INC | 4 | Q3 2023 | 2.8% |
| XENON PHARMACEUTICALS INC | 4 | Q3 2023 | 2.5% |
View BRAIDWELL LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G | 2023-02-14 |
| SC 13G | 2023-02-14 |
View BRAIDWELL LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.